Polycystic Ovary Syndrome / 고신대학교의과대학학술지
Kosin Medical Journal
;
: 109-114, 2015.
Artigo
em Inglês
| WPRIM
| ID: wpr-193809
ABSTRACT
Polycystic ovary syndrome affects 6%-7% of reproductive-aged women, making it the most common endocrine disorder in this population. It is characterized by chronic anovulation and hyperandrogenism. Affected women may present with reproductive manifestations such as irregular menses or infertility, or cutaneous manifestations, including hirsutism, acne, or male-pattern hair loss. Over the past decade, several serious metabolic complications also have been associated with polycystic ovary syndrome including type 2 diabetes mellitus, metabolic syndrome, sleep apnea, and possibly cardiovascular disease and nonalcoholic fatty liver disease. In addition to treating symptoms by regulating menstrual cycles and improving hyperandrogenism, it is imperative that clinicians recognize and treat metabolic complications. Lifestyle therapies are first-line treatment in women with polycystic ovary syndrome, particularly if they are overweight. Pharmacological therapies are also available and should be tailored on an individual basis. This article reviews the diagnosis, clinical manifestations, metabolic complications, and treatment of the syndrome.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Síndrome do Ovário Policístico
/
Síndromes da Apneia do Sono
/
Resistência à Insulina
/
Doenças Cardiovasculares
/
Acne Vulgar
/
Hiperandrogenismo
/
Diabetes Mellitus
/
Diabetes Mellitus Tipo 2
/
Diagnóstico
/
Sobrepeso
Tipo de estudo:
Estudo diagnóstico
Limite:
Feminino
/
Humanos
Idioma:
Inglês
Revista:
Kosin Medical Journal
Ano de publicação:
2015
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS